Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer

B. T. F. van der Gun, C. Huisman, S. Stolzenburg, H. G. Kazemier, M. H. J. Ruiters, P. Blancafort, M. G. Rots*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

17 Citaten (Scopus)
201 Downloads (Pure)

Samenvatting

Background: The epithelial cell adhesion molecule (EpCAM) is overexpressed on most carcinomas. Dependent on the tumour type, its overexpression is either associated with improved or worse patient survival. For ovarian cancer, however, the role of EpCAM remains unclear.

Methods: Cell survival of ovarian cancer cell lines was studied after induction or repression of endogenous EpCAM expression using siRNA/cDNA or artificial transcription factors (ATF) consisting of engineered zinc-fingers fused to either a transcriptional activator or repressor domain.

Results: Two ATFs were selected as the most potent down- and upregulator, showing at least a two-fold alteration of EpCAM protein expression compared with control. Downregulation of EpCAM expression resulted in growth inhibition in breast cancer, but showed no effect on cell growth in ovarian cancer. Induction or further upregulation of EpCAM expression decreased ovarian cancer cell survival.

Conclusion: The bidirectional ATF-based approach is uniquely suited to study cell-type-specific biological effects of EpCAM expression. Using this approach, the oncogenic function of EpCAM in breast cancer was confirmed. Despite its value as a diagnostic marker and for immunotherapy, EpCAM does not seem to represent a therapeutic target for gene expression silencing in ovarian cancer.

Originele taal-2English
Pagina's (van-tot)881-886
Aantal pagina's6
TijdschriftBritish Jounal of Cancer
Volume108
Nummer van het tijdschrift4
DOI's
StatusPublished - 5-mrt.-2013

Citeer dit